Kornimate/medical-research-clean huggingface dataset:
comparison of post-inflammatory pigment alteration after psoriasis treatment (pipa - dermavant)

Conditions: ICD10 Code L40.9 for Psoriasis

Summary: the purpose of this prospective study is to evaluate the degree of post-inflammatory pigmentation alteration on legs of study subjects treated with two different psoriasis treatments. betamethasone dipropionate 0.05% cream is a high potency steroid that is commonly used to alleviate the inflammation of psoriasis. tapinarof is another medication approved for psoriasis; tapinarof activates aryl hydrocarbon receptors to downregulate inflammatory cytokines (such as interleukin \[il\]-17) which play a large role in psoriasis. study subjects will be randomized to receive one of these medications and will be followed to monitor for pipa. photographs will be taken to help evaluate visual changes. the taylor hyperpigmentation scale will be used to grade the area and severity of hyperpigmentation and hypopigmentation; severity of erythema, burning, peeling, and dryness will also be recorded. this will allow us to understand the effects of two standard-of-care psoriasis medications to better treat patients.

subjects will be randomized to either of the two treatment groups (betamethasone dipropionate or tapinarof) and will be treated with that medication for until clear or up to 12 weeks . photographs will be taken before and after treatment. the betamethasone dipropionate 0.05% cream group will be treated with betamethasone dipropionate 0.05% cream once daily on both legs until clear or up to 12 weeks. the tapinarof group will be treated with 1% tapinarof cream applied once daily to both legs until clear or up to 12 weeks. subjects will return every 4 weeks for evaluation. if disease recurs after clearing, treatment will be re-instituted. both groups will also be followed up at 1 and 4 weeks after end of treatment to monitor for pipa and any other after-treatment effects. healthcare providers and patients may benefit from the information obtained during this study; study subjects may directly benefit from participation as they will be treated with standard treatments for psoriasis. we hope the information gathered will help healthcare providers better serve patients and identify psoriasis treatment after-effects.

Eligibility criteria:
inclusion criteria: 1. adults (age 18+) with fitzpatrick skin type 3 or higher who have been diagnosed with icd10 code l40.9 for psoriasis between \[dates\] at atrium health wake forest baptist medical center. 2. stable on other therapies such as biologics for at least 3 months before randomization. exclusion criteria: 1. lack of a diagnosis of psoriasis (icd10 code l40.9) or fitzpatrick skin type below 3. 2. pigmentary changes that in the opinion of the investigator would compromise the ability to assess the study outcomes.
a clinical study of dihydroergotine mesylate extended-release tablets for the treatment of drooling in parkinson's disease.

Conditions: Salivation in Parkinson's Disease

Summary: objective: to evaluate the efficacy and safety of dihydroergotine mesylate extended-release tablets for salivation in parkinson\&#39;s disease study content: using a randomized, double-blind, placebo-controlled study design, 120 patients with parkinson\&#39;s disease and cognitive impairment were enrolled, and the treatment was followed up for 12 weeks: dihydroergotine mesylate sustained-release tablets + conventional treatment (treatment group patients, 80 cases), placebo + conventional treatment (control group patients, 40 cases), and the main indicators were observed: the improvement effect of dihydroergotine mesylate sustained-release tablets on pd salivation was observed, and the secondary indicators were observed: the effect of dihydroergotine mesylate sustained-release tablets on the cognitive function of pd patients was observed. expected results: the improvement effect of dihydroergotine mesylate sustained-release tablets on pd salivation was significantly different from that of the placebo control group. the dihydroergotine mesylate sustained-release tablet group had a significant effect on the cognitive function of pd patients.


Eligibility criteria:
inclusion criteria: 1. patients with parkinson\&#39;s disease diagnosed by the british parkinson\&#39;s disease brain bank diagnostic criteria can come to the hospital accompanied by family members 2. drooling score using the parkinson\&#39;s comprehensive rating scale (updrs) part ii (item 6) ≥3; 3. mmse ≥ 10 points (recording the patient\&#39;s education level) 4. adults over the age of 18 5. the applicant or his/her caregiver must be able to complete the record of the salivation score 6. patients or family members voluntarily participate and sign an informed consent form. exclusion criteria: 1. patients with non-primary parkinson\&#39;s disease 2. known allergy to dihydroergotamine mesylate 3. drug-induced hypersalivation, such as olanzapine, antipsychotics, clonazepam and other antiepileptic drugs, as well as direct and indirect cholinergic agonists for the treatment of alzheimer\&#39;s disease and myasthenia gravis 4. bont treatment for saliva within the previous 3 months 5. patients with symptomatic bradycardia, severe orthostatic hypotension, symptomatic coronary insufficiency, severe organic cardiac damage, severe liver and kidney insufficiency: including alt≥2.5uln (upper limit of normal value of the executive laboratory); ast≥2.5uln (upper limit of normal for the execution laboratory); creatinine ≥ 1.5 uln (upper limit of normal at the execution laboratory), active psychosis, pregnancy/pregnant woman
validating niaaa screen guide in ycmc

Conditions: Alcohol Related Disorders

Summary: alcohol use is a serious health threat to the 26% youth in the us with chronic medical conditions. while alcohol use can significantly impact an underlying illness and its safe/effective management, medical specialists rarely screen their adolescent patients for alcohol use. the investigators will validate a new, brief alcohol- screening tool with 9-18 year old youth with chronic medical conditions. comprehensive assessment information will be collected and analyzed to describe relationships between youth alcohol use, other substance use, and chronic disease outcomes and findings integrated into the validated screen as actionable clinician guidance and health advice.


Eligibility criteria:
inclusion criteria: * 9-18 years of age * duration of chronic illness of at least one year * ability to speak/read english and use a computer keyboard and/or complete an interviewer-assisted questionnaire exclusion criteria: * medically or emotionally unstable * unable to assent/consent

Keywords: alcohol related disorders
characterization of circulating tumor cells (ctc-s) in patients with locally advanced or metastatic stage iv breast cancer

Conditions: Locally Advanced Breast Cancer; Metastatic (Stage IV) Breast Cancer; Stage III-IV Breast Cancer or Inflammatory

Summary: the purpose of this study is to identify tumor cells in the bloodstream (circulating tumor cells, ctc's) from patient's with locally advanced or metastatic (stage iv) breast cancer. analyzing the tumor is helpful in guiding therapy; however, research has suggested that the number of tumor cells found in the bloodstream (ctc's) signifies more aggressive behavior and increased difficulty in eliminating the cancer. this research will help to develop better ways to treat breast cancer which could be tailored to a patient and may be adjusted to a patient's individual needs.

up to 60 ml of blood will be collected from each patient at up to 6 time points. samples will be delivered to the bruce laboratory (palo alto research center) for immunolabeling and fast scanning. the fast scanning will utilize ck+, cd45-and dapi+ labeling as well as cell morphology confirmed by collaborating pathologists to select for ctc with the technology allowing for assessment of up to four additional protein expressions on the surface of ctc's. additional samples at the proposed time points will be placed on ice and sent over to the wang laboratory for the purpose of extracting rna/microrna and proteins from ctc's for profiling and further analysis. benefits are only to society, not the individual. knowledge obtained from applying the two technologies may help with better selection of therapy, early detection of progression, possibly better diagnosis and development of targeted therapeutic agents in the future.

Eligibility criteria:
inclusion criteria: * patients must be \> 18 years old. * patients are being treated for breast cancer at city of hope (coh).

Keywords: circulating tumor cells in breast cancer
animovil mhealth support for depression management in a low-income country

Conditions: Depression

Summary: depression is a huge public health problem in low and middle-income countries (lmics). mental health care systems in most lmics are extremely limited, impeding the dissemination of who-recommended models for improving care via "task-shifting" services to community health workers (chws) who deliver evidence-based treatments such as cognitive behavioral therapy (cbt). this comprehensive intervention will use ivr and text messaging (sms) to support effective depression care. intervention patients will receive weekly automated (ivr) calls and daily text messages (sms) throughout the 12 week intervention. patients with more severe depression will receive up to 12 weekly chw-delivered telephone cbt sessions, based on who recommendations and a treatment model developed and tested in india. chws will use patients' ivr contacts to enhance psychoeducation and they will use sms plus web-based reports based on patients' ivr calls to identify individuals needing additional follow-up. the chws' clinical supervisor will use sms messages to chws to reinforce best practices and monitor service delivery. patients will be enrolled from colombian clinics associated with the universidad de los andes in bogota, colombia. 114 patients will be randomized to either a usual enhanced care or intervention group. intervention group patients will receive weekly automated (ivr) calls and daily text messages throughout the duration of the 12 week intervention. patients with more severe depression will receive up to 12 weekly chw-delivered telephone cbt sessions, based on who recommendations and a treatment model developed and tested in india. chws will use patients' ivr contacts to enhance psychoeducation and they will use sms plus web-based reports based on patients' ivr calls to identify individuals needing additional follow-up. the chws' clinical supervisor will use sms messages to chws to reinforce best practices and monitor service delivery. program components will be modified to fit the local culture and clinical environment via iterative engagement of health professionals and patients with depression. those patients in usual enhanced care will receive the study manual and daily text messages and feedback throughout the duration of the program. patients in the enhanced usual care group who present with more severe depression will be referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression.


Eligibility criteria:
inclusion criteria: * a score of 10+ on the spanish-validated version of the phq-9 exclusion criteria: * less than a 6-month life expectancy * a history of psychiatric hospitalization or bipolar disorder * a substance use disorder or cognitive impairment
evaluation of non inferiority of non capsular suture in femoroacetabular impingement arthroscopic treatment

Conditions: Femoral Acetabular Impingement

Summary: since last past decade, arthroscopic hip surgery proved its efficacy in femoroacetabular impingement treatment. however, no consensus exist concerning capsular suture or not. according to capsular incision size, articular instability can persist if no suture is performed. in contrast, tightly suture can cause post-operative joint stiffness. this study aims to evaluate the non inferiority of non capsular suture after hip arthroscopy treatment of cam or mixed-type femoroacetabular impingement, without hip dysplasia, after 2 years follow-up.

main objective : non inferiority evaluation of non capsular suture after hip arthroscopy treatment of cam or mixed-type femoroacetabular impingement, without hip dysplasia, after 2 years follow-up. the primary study endpoint is the patient reported outcomes (hagos score; ihot-12 and mhhs) at 2 years follow-up. secundary objectives : * clinical results at 6 month and 1 year follow-up * specific complications occuring and frequences * patient quality of life, * the return to sport, * sport level after surgery compare to sport level before surgery * pain

Eligibility criteria:
inclusion criteria: * patient \< 18 years old * patient who can be followed for 2 years * patient with confirmed diagnostic of femoroacetabular impingement came or mixed-types, without dysplasia and with vce angle \> 25°, without prearthrosic lesion and tonnis 0 ou tonnis 1, radiographic assement * patient must sign an informed consent form indicating that he or she understands the purpose of procedure required for the study and accepts to participate in the study. * patient affiliated to a social security system exclusion criteria: * patient with no wittren informed consent * patient presenting osteoarthritis (tonnis stage 2) or only pincer impingement * hyperlaxity * dysplasia (vce \<25°) * patient already underwent hip arthroscopy * patient already underwent previous hip surgery * patient needing bilateral hip arthroscopy \< 2 years * persons deprived of their freedom or under guardianship or incapable of giving consent

Keywords: hip arthroscopy capsular suture femoral acetabular impingement
control of head lice infestations in children and adults

Conditions: Pediculosis

Summary: the goal of this study is to see if heated air will kill head lice and their eggs. the treatment visit is approximately 1 hour long with a follow up phone call.

head lice strikes fear into the hearts of parents of school age children. ridding a child of head lice is one of the most frustrating experiences a parent can face. the objective of this project is to test whether louse desiccation using our prototype is an effective means of controlling head louse infestations in children. children age 6 and over are included in this study.

Eligibility criteria:
inclusion criteria: * must be at least 6 years old, male or female parent to attend treatment able to comb the hair with no problems exclusion criteria: * chemical shampoos used within 14 days open sores or wounds on the scalp recent head radiation

Keywords: head lice
impact of steroids on inflammatory response in covid-19

Conditions: Covid19

Summary: we designed this study to observe the efficacy and safety of dexamethasone versus methylprednisolone in covid-19 diseased patients upon monitoring the inflammatory response and to compare the outcome when these steroids will be given in covid-19 diseased patients in our icu.

a written informed consent will be taken from the patients or their relatives. the study will involve adults (age 18-no limit years) who will be diagnosed covid-19 with destructive inflammatory immune response needing icu admission to be run on steroid therapy. patients will be assigned randomly to two groups (30 subjects each). the study drug will be delivered in opaque bags labeled "study drug" and in (group d) intravenous dexamethasone 8 mg/day given for 7 days, in (group m) intravenous methylprednisolone 1 mg/kg/day in 2 divided doses per day given for 7 days.

Eligibility criteria:
inclusion criteria: * adults (age 18-no limit years) who will be diagnosed covid-19 * with destructive inflammatory immune response needing icu admission to be run on steroid therapy. exclusion criteria: * severe immunosuppression like hiv (human immunodeficiency virus) * long term use of immunosuppressant for any other chronic illness * pregnant or lactating females * patients who are on chronic use of corticosteroids like asthma, rheumatoid arthritis.
sintilimab and nab-paclitaxel in second-line treatment of advanced gastric or gastro-oesophageal junction adenocarcinoma

Conditions: Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma

Summary: to evaluate the efficacy and safety of sintilimab (pd-1 inhibitor) and nab-paclitaxel in second line treatment of advanced gastric and gastro-esophageal junction adenocarcinoma. this is a prospective, multi-centers, single arm phase ii trial with primary objective overall response rate and second objective of safety and other efficacy endpoints.


Eligibility criteria:
inclusion criteria: * pathological confirmed advanced gastric and gastro-esophageal junction adenocarcinoma; * progression after first-line treatment of fluoropyrimidine and platinum, allow patients progressed on/within 6 months of neoadjuvant/adjuvant treatment; allow local radiotherapy after 21days later; * 18-75 years old; * ecog: 0 or 1; * has adequate organ function * writen icf; exclusion criteria: * previous treated with taxanes (including paclitaxel, nab-ptx, lipo-ptx, and docetaxel etc..); * has received prior therapy with an anti-pd-1, anti-pd-l1, or anti-ctla-4 antibody; * has known active central nervous system metastatases; * has received a live vaccine within 4 weeks prior to the first dose of study treatment with any acitve autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatititis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. * clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, congestive heart failure (new york heart association (nyha) class \> 2), orventricular arrhythmia which need medical intervention. * hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg. coagulation abnormalities (inr \> 1.5 or aptt \> 1.5×uln), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy.

Keywords: second line pd-1 nab-paclitaxel
efficacy of ranibizumab prn treatment compared to aflibercept bimonthly intravitreal injections on retinal thickness stability in patients with wet amd

Conditions: Neovascular Age-related Macular Degeneration

Summary: the purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.

patients attended 14 scheduled study visits during 12 months.

Eligibility criteria:
key inclusion criteria: * visual impairment predominantly due to neovascular amd active * newly diagnosed, untreated, angiographically documented choroidal neovascularization (cnv) lesion key exclusion criteria: * stroke or myocardial infarction less than 3 months prior to study entry * active injection or inflammation of either eye at the time of study entry * any type of systemic disease (or received treatment for it), including any medical condition (controlled or uncontrolled) that were to be expected to progress, recur, or change to an extent which could bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk

Keywords: wet age-related macular degeneration (amd) ranibizumab aflibercept best corrected visual acuity (bcva) spectral domain optical coherence tomography (sd-oct)
role of new adipokines and hepatokines in prediction of patients with metabolic syndrome or nafld

Conditions: Non-alcoholic Fatty Liver Disease; Type 2 Diabetes; Metabolic Syndrome

Summary: to investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (nafld), diabetes, or dyslipidmia. to examine the association or effects of clinical and biochemical factors (lab results and medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with non-alcoholic fatty liver disease (nafld), diabetes, or dyslipidmia.


Eligibility criteria:
inclusion criteria: 1. dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum ldl-c≥100mg/dl, or taking medication to lower ldl-c levels (e.g. statin, ezetimibe, etc.) 2. type 2 diabetes 1. defined according to the ada guideline (dm definition) or 2. taking any anti-diabetic medications 3. non-alcoholic fatty liver disease (nafld) 1. diagnosed as having fatty liver by ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram (fibroscan) or 3. diagnosed as having fatty liver by abdomina ct scan 4. normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. bmi \<25kg/m2 exclusion criteria: 1. subjects who refused to agree with informed consents 2. subjects with organ-transplantation 3. serum creatinine ≥1.5mg/dl 4. pregnant women 5. liver cancer or pancreatic cancer 6. subjects with chronic hepatitis b or c virus infection 7. for nafld group, subjects with excessive alcohol consumption (men: ≥210g of alcohol per week, women: ≥140g of alcohol per week)
a study to evaluate safety and pk of multiple doses of lt3001 drug product and drug-drug interaction in healthy subjects

Conditions: Acute Ischemic Stroke

Summary: this phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of lt3001 drug product and to investigate drug interactions of lt3001 with potential concomitant medications in healthy subjects.

this study is a two-part study. part a is double-blind, placebo-controlled, and will examine the safety and pk profiles of multiple doses of lt3001 drug product in healthy subjects. part b is open-label and will assess the safety and pk of lt3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.

Eligibility criteria:
inclusion criteria: * subject's body weight is ≥50 kg and bmi is within the range of 18 to 32 * subject is a healthy volunteer. * subject's pt, aptt, and tt are within the normal laboratory range. * subject is a nonsmoker exclusion criteria: * subject has a current or recent history of regular alcohol consumption. * subjects who are enrolled in part b and allergic to acetylsalicylic acid, other salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or dabigatran. * part b cohort 2 only: subjects who are poor metabolizers of clopidogrel (cyp2c19\*2/\*2, \*2/\*3, or \*3/\*3 genotype) * subject has a presence or history of coagulation abnormality. * subjects need to receive a surgery or clinical procedures associated with high bleeding risk. * subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding, gingival bleeding. * subject has a history of peptic ulcer or gastrointestinal bleeding.